XML 40 R50.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Summary of Revenue Recognized under Agreement with GSK (Detail) (USD $) In Thousands, unless otherwise specified | 3 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Dec. 31, 2013 | Sep. 30, 2013 | Jun. 30, 2013 | Mar. 31, 2013 | Dec. 31, 2012 | Sep. 30, 2012 | Jun. 30, 2012 | Mar. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 National Institutes of Health | Dec. 31, 2012 National Institutes of Health | Dec. 31, 2011 National Institutes of Health | Dec. 31, 2008 Glaxo, Smith, Kline | Dec. 31, 2013 Glaxo, Smith, Kline | Dec. 31, 2012 Glaxo, Smith, Kline | Dec. 31, 2011 Glaxo, Smith, Kline | Dec. 31, 2013 Astra Zeneca | Dec. 31, 2012 Astra Zeneca | Dec. 31, 2011 Astra Zeneca | Dec. 31, 2013 National Institute Of Allergy And Infectious Diseases | Dec. 31, 2012 National Institute Of Allergy And Infectious Diseases | Dec. 31, 2011 National Institute Of Allergy And Infectious Diseases
Product Information [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Initial payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000 | $ 1,702 | $ 1,428 | $ 1,428 | $ 720 | $ 720 | $ 120 |  |  |
Milestone revenue |  |  |  |  |  |  |  |  |  |  | 12,000 |  |  |  |  |  |  | 15,000 | 2,507 | 2,462 | 642 |  |  |
Total revenues | 2,847 | 2,927 | 3,392 | 2,085 | 1,806 | 2,874 | 2,684 | 2,350 | 11,251 | 9,714 | 21,614 |  |  |  |  | 1,702 | 1,428 | 16,428 | 3,227 | 3,182 | 762 |  |  |
Grant revenue |  |  |  |  |  |  |  |  | $ 5,138 | $ 3,939 | $ 3,110 | $ 1,035 | $ 368 | $ 380 |  |  |  |  |  |  |  | $ 4,103 | $ 3,571 | $ 2,730

X
- Definition Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueAdditions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ProductInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_RevenueFromGrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration